drugset / Trial / NCT00264147
Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the clinically active dose range of study medication in the treatment of patients with rheumatoid arthritis.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-03
- Completion
- 2008-03
Outcome
Met primary endpoint
paper Etoricoxib 90 mg was the only dose to reach a statistically significant difference from placebo (p < 0.001) on the primary endpoint; PMID 21905970 ↗
Publications
- Results Greenwald M, Peloso PM, Mandel D, Soto O, Mehta A, Frontera N, Boice JA, Zhan XJ, Curtis SP. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis. Curr Med Res Opin. 2011 Oct;27(10):2033-42. doi: 10.1185/03007995.2011.614935. Epub 2011 Sep 12.
- Kvien TK, Greenwald M, Peloso PM, Wang H, Mehta A, Gammaitoni A. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskelet Disord. 2015 Feb 13;16:26. doi: 10.1186/s12891-015-0468-7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diclofenac | Other / unclassified | 75 mg | — |
| Subject | Etoricoxib | Small molecule | 10 mg | — |
| Subject | Etoricoxib | Small molecule | 30 mg | — |
| Subject | Etoricoxib | Small molecule | 60 mg | — |
| Subject | Etoricoxib | Small molecule | 90 mg | — |